The transplant team presented the topic Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed B-cell Acute Lymphoblastic at the congress Preliminary research results show that the current transplantation strategy can make these refractory/relapsed B-ALL patients with little hope of cure obtain excellent treatment results,with the 6-month overall survival rate of 96.9%and disease-free survival rate of 91.7%.